A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Healthy

Interventions

BIOLOGICAL

RN316

Single, escalating doses of RN316 administered IV. Doses planned for testing = 0.3, 1.0, 3.0, 6.0, 12.0, and 18.0 mg/kg.

Trial Locations (2)

Pfizer Investigational Site, Miami Gardens

Pfizer Investigational Site, Phoenix